Lunge Snehal, Bhise Rohan
Assistant Prof., Dept. of Dermatology, JNMC, BELGAum, Karnataka.
Consulting Oncologist, KLES Dr. Prabhakar Kore Hospital, Belgaum, Karnataka.
J Assoc Physicians India. 2018 Dec;66(12):79-80.
Imatinib, a specific tyrosine kinase inhibitor is a new anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is well tolerated with few side effects. Commonest adverse events are maculopapular eruptions and periorbital edema were reported. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 55-year-old female who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
伊马替尼是一种特异性酪氨酸激酶抑制剂，是一种新型抗癌药物，在治疗慢性粒细胞白血病方面显示出优异的疗效。它耐受性良好，副作用较少。报告的最常见不良事件是斑丘疹和眶周水肿。5%的患者出现严重不良反应。使用该药物很少报告有剥脱性皮炎。我们报告一例55岁女性患者，最初表现为斑丘疹，在继续用药后发展为红皮病。
